BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mesutoclax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mesutoclax\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06656494-2932@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Mesutoclax: Phase 1 readout est. (NCT06656494)
DESCRIPTION:Mesutoclax\, phase 1\, Acute Myeloid Leukemia.\nStudy: ICP-248 
 in Combination With Azacitidine for the Treatment in Patients With Myeloid
  Malignancies\nEstimated primary completion: June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/mesutoclax#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06656494
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351527-2932@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Mesutoclax: Phase 1 readout est. (NCT06351527)
DESCRIPTION:Mesutoclax\, phase 1.\nStudy: Evaluate the Safety\, Tolerabilit
 y\, Pharmacokinetics\, and Preliminary Efficacy of ICP-248 as Monotherapy 
 or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Mali
 gnancies\nEstimated primary completion: 25 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/mesutoclax#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06351527
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082686-2932@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mesutoclax: Phase 2 readout est. (NCT07082686)
DESCRIPTION:Mesutoclax\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study to
  Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or 
 Refractory Mantle Cell Lymphoma (APEX-06)\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mesutoc
 lax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07082686
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896590-2932@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07896590)
DESCRIPTION:Mesutoclax\, phase 3.\nStudy: Orelabrutinib Plus ICP 248 vs Ore
 labrutinib for Relapsed/Refractory Marginal Zone Lymphoma\nEstimated prima
 ry completion: October 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mesutoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07896590
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925190-2932@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07925190)
DESCRIPTION:Mesutoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study 
 Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untr
 eated Acute Myeloid Leukemia (AML) Patients\nEstimated primary completion:
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mesut
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07925190
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378138-2932@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20301125
DTEND;VALUE=DATE:20301126
SUMMARY:Mesutoclax: Phase 2/3 readout est. (NCT06378138)
DESCRIPTION:Mesutoclax\, phase 2/3\, Chronic Lymphocytic Leukemia.\nStudy: 
 ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymp
 hocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)\nEstimated primary c
 ompletion: 25 November 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/mesutoclax#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06378138
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784101-2932@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20321031
DTEND;VALUE=DATE:20321101
SUMMARY:Mesutoclax: Phase 3 readout est. (NCT07784101)
DESCRIPTION:Mesutoclax\, phase 3\, Mantle Cell Lymphoma.\nStudy: A Phase 3 
 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib
  Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle C
 ell Lymphoma (r/r MCL).\nEstimated primary completion: October 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/mesutoclax#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07784101
URL:https://assetmemo.bio/drug/mesutoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
